公开(公告)号：US20140065226A1

公开(公告)日：2014-03-06

申请号：US13261732

申请日：2012-03-05

Applicant: Eric Brey ,  Jennifer J. Kang-Mieler ,  Victor Perez-Luna ,  Bin Jiang ,  Pawel Drapala ,  Rolf Schäfer ,  Hans Hitz

Inventor： Eric Brey ,  Jennifer J. Kang-Mieler ,  Victor Perez-Luna ,  Bin Jiang ,  Pawel Drapala ,  Rolf Schäfer ,  Hans Hitz

IPC: A61K47/32 ,  A61K31/573

CPC classification number: A61K47/32 ,  A61K9/0014 ,  A61K9/0048 ,  A61K9/06 ,  A61K9/5153 ,  A61K31/573 ,  A61K47/34

Abstract: A thermo-responsive hydrogel, including a biocompatible monomer and/or polymer having a side chain-linked amino acid. The hydrogel is thermo-responsive at a physiological temperature, and can include, incorporate, or encapsulate a treatment agent, such as a drug composition, a biomolecule, and/or a nano-particle. The hydrogel is useful in delivering the treatment agent. The hydrogel is in a first physicochemical state for administration to a mammal. The hydrogel is thermo-responsive at a physiological temperature of the mammal, and changes to a second physicochemical state that is more solid than the first physicochemical state. In the second physicochemical state the thermo-responsive hydrogel releases the treatment agent.

Abstract translation: 一种热响应性水凝胶，包括具有侧链连接的氨基酸的生物相容性单体和/或聚合物。 水凝胶在生理温度下是热响应的，并且可以包括，掺入或包封处理剂，例如药物组合物，生物分子和/或纳米颗粒。 水凝胶可用于递送处理剂。 水凝胶处于哺乳动物的第一物理化学状态。 水凝胶在哺乳动物的生理温度下是热应答的，并且变成比第一物理化学状态更固体的第二物理化学状态。 在第二个物理化学状态下，热响应性水凝胶释放处理剂。

公开(公告)号：US08324401B2

公开(公告)日：2012-12-04

申请号：US12542762

申请日：2009-08-18

Applicant: Jingwu Duan ,  Bin Jiang

Inventor： Jingwu Duan ,  Bin Jiang

IPC: A61K31/4164 ,  A61K31/426 ,  C07D233/54

CPC classification number: C07D285/135 ,  C07D233/76 ,  C07D249/12 ,  C07D277/46 ,  C07D285/08

Abstract: Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I): or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is A1QA2-; Q is a bond, —C(═O)—, —OC(O)—, —C(═O)NR5—, —SOp—, —SOpNR5—, —C(O)O—, —NR5C(O)—, —OC(O)NR5—, —NR5C(O)O—, —S(O)pNR5C(O)—, —C(O)NR5S(O)p— —NR5S(O)p—, or —NR5C(═O)NR6—. Y is selected from hydrogen, C1-6alkyl, OR16, substituted C1-6alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A1 and A2 are independently selected from a bond, C1-3alkylene, or C1-3alkenylene, and R1-R11 are defined herein. Also provided are pharmaceutical compositions, combinations, and methods of treating obesity, diabetes and inflammatory- or immune-associated diseases comprising said compounds.

Abstract translation: 提供新的非甾体化合物，其可用于治疗与糖皮质激素受体，AP-1和/或NF-κB活性相关的疾病，所述疾病包括具有式（I）结构的肥胖症，糖尿病，炎症和免疫疾病 ）：或其对映异构体，非对映体或其药学上可接受的盐或水合物，其中X为AlQA2-; Q是键，-C（= O） - ， - OC（O） - ， - C（= O）NR5-，-SOp-，-SOpNR5-，-C（O） - （O）NR 5 - ， - NR 5 C（O）O-，-S（O）pNR 5 C（O） - ， - C（O）NR 5 S（O） NR5C（= O）NR6-。 Y选自氢，C 1-6烷基，OR 16，取代的C 1-6烷基，环烷基，芳基，杂环和杂芳基。 A1和A2独立地选自键，C1-3亚烷基或C1-3亚烯基，R1-R11在本文中定义。 还提供了治疗包含所述化合物的肥胖症，糖尿病和炎性或免疫相关疾病的药物组合物，组合和方法。

公开(公告)号：US08018751B1

公开(公告)日：2011-09-13

申请号：US12504523

申请日：2009-07-16

Applicant: Dinesh Maheshwari ,  Andrew Wright ,  Bin Jiang ,  Bartosz Banachowicz

Inventor： Dinesh Maheshwari ,  Andrew Wright ,  Bin Jiang ,  Bartosz Banachowicz

IPC: G11C15/00

CPC classification number: G11C15/04

Abstract: A ternary content addressable memory (TCAM) cell circuit formed in a TCAM memory cell array having cells arranged in rows and columns can include a first storage circuit with first and second data path, a second storage circuit with a third and fourth data path, and a compare circuit. No more than four conductive lines in a column wise direction have a direct electrical connection to the TCAM cell. Such conductive lines can include a first bit line coupled to the first data path and the third data path and a second bit line coupled to the second data path and the fourth data path.

Abstract translation: 形成在具有排列成行和列的单元的TCAM存储单元阵列中的三元内容可寻址存储器（TCAM）单元电路可以包括具有第一和第二数据路径的第一存储电路，具有第三和第四数据路径的第二存储电路，以及 比较电路。 在列方向上不超过四条导线与TCAM电池有直接电连接。 这样的导线可以包括耦合到第一数据路径和第三数据路径的第一位线和耦合到第二数据路径和第四数据路径的第二位线。

公开(公告)号：USD635136S1

公开(公告)日：2011-03-29

申请号：US29352726

申请日：2009-12-23

Applicant: Bin Jiang ,  Te-Hua Lee

Designer： Bin Jiang ,  Te-Hua Lee

公开(公告)号：US07625921B2

公开(公告)日：2009-12-01

申请号：US11034822

申请日：2005-01-13

Applicant: Jingwu Duan ,  James Sheppeck ,  Bin Jiang ,  John L. Gilmore

Inventor： Jingwu Duan ,  James Sheppeck ,  Bin Jiang ,  John L. Gilmore

IPC: A61K31/4748 ,  C07D401/14 ,  C07D417/12

CPC classification number: C07D471/08 ,  C07D401/12 ,  C07D401/14 ,  C07D417/12 ,  C07D417/14

Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least one of X1-X8 is N, and R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

Abstract translation: 提供了一类新型非甾体化合物，其可用于治疗与糖皮质激素受体，AP-1和/或NF-κB活性的调节相关的疾病，包括肥胖症，糖尿病，炎症和免疫疾病，并且具有 式（I）其立体异构体，或其溶剂合物或其前药，或其药学上可接受的盐，其中Z为CONR1R2或CH2NR1R2，并且其中X1-X8中的至少一个为N，R，Ra，Rb， Rc和Rd在本文中定义。 还提供了治疗肥胖症，糖尿病和包含所述化合物的炎性或免疫相关疾病的药物组合物和方法。

公开(公告)号：US07592461B2

公开(公告)日：2009-09-22

申请号：US11642508

申请日：2006-12-20

Applicant: Jingwu Duan ,  Bin Jiang

Inventor： Jingwu Duan ,  Bin Jiang

IPC: A61K31/426 ,  A61K31/433 ,  C07D277/46 ,  C07D285/135

CPC classification number: C07D285/135 ,  C07D233/76 ,  C07D249/12 ,  C07D277/46 ,  C07D285/08

Abstract: Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I): or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is -A1QA2-; Q is a bond, —C(═O)—, —OC(O)—, —C(═O)NR5—, —SOp—, —SOpNR5—, —C(O)O—, —NR5C(O)—, —OC(O)NR5—, —NR5C(O)O—, —S(O)pNR5C(O)—, —C(O)NR5S(O)p— —NR5S(O)p—, or —NR5C(═O)NR6—. Y is selected from hydrogen, C1-6alkyl, OR16, substituted C1-6alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A1 and A2 are independently selected from a bond, C1-3alkylene, or C1-3alkenylene, and R1-R11 are defined herein. Also provided are pharmaceutical compositions, combinations, and methods of treating obesity, diabetes and inflammatory- or immune-associated diseases comprising said compounds.

Abstract translation: 提供了新型非甾体化合物，其可用于治疗与调节糖皮质激素受体，AP-1和/或NF-κB活性相关的疾病，包括具有式（I）结构的肥胖症，糖尿病，炎症和免疫疾病： 或对映异构体，非对映异构体或其药学上可接受的盐或水合物，其中X为-A1QA2-; Q是键，-C（-O） - ， - OC（O） - ， - C（-O）NR5-，-SOp-，-SOpNR5-，-C（O） - （O）NR 5 - ， - NR 5 C（O）O-，-S（O）p NR 15 C（O） - ， - C（O）NR 5 S（O）p - ， - -NR 5 C（-O）NR 6 - 。 Y选自氢，C 1-6烷基，OR 16，取代的C 1-6烷基，环烷基，芳基，杂环和杂芳基。 A1和A2独立地选自键，C1-3亚烷基或C1-3亚烯基，R1-R11在本文中定义。 还提供了治疗包含所述化合物的肥胖症，糖尿病和炎性或免疫相关疾病的药物组合物，组合和方法。

公开(公告)号：US07579873B1

公开(公告)日：2009-08-25

申请号：US11985706

申请日：2007-11-16

Applicant: Bin Jiang ,  Sang Kong Chan

Inventor： Bin Jiang ,  Sang Kong Chan

IPC: H03K19/0175 ,  H03K3/00

CPC classification number: H03K5/01 ,  H03K5/06

Abstract: An interface driver circuit comprises N cascaded delay cells, each including a data bit input, a delayed data bit output that communicates with the data bit input of an adjacent one of the N cascaded delay cells, and a delay time input that sets delay values between receiving data at the data bit input and generating the delayed data bit output. N predrivers receive an output enable signal that is independent of the data, receive a corresponding one of the N delayed data bit outputs and generate a predriver output signal based on the output enable signal and the corresponding one of the N delayed data bit outputs.

Abstract translation: 一个接口驱动电路包括N个级联延迟单元，每个包括数据位输入，与N个级联延迟单元相邻的数据位输入通信的延迟数据位输出，以及延迟时间输入， 在数据位输入端接收数据并产生延迟的数据位输出。 N个预取器接收独立于数据的输出使能信号，接收N个延迟的数据位输出中的相应一个，并且基于输出使能信号和N个延迟的数据位输出中的相应一个产生预驱动输出信号。

公开(公告)号：US07569689B2

公开(公告)日：2009-08-04

申请号：US11034652

申请日：2005-01-13

Applicant: Jingwu Duan ,  Bin Jiang ,  James Sheppeck ,  John L. Gilmore

Inventor： Jingwu Duan ,  Bin Jiang ,  James Sheppeck ,  John L. Gilmore

IPC: A61K31/498 ,  C07D417/14

CPC classification number: C07D403/12 ,  C07D241/36 ,  C07D417/12 ,  C07D417/14

Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least two of X1-X4 and/or X5-X8 is N or NR18, and R, Ra, Rb, Rc, Rd, R1, R2 and R18 are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

Abstract translation: 提供了一类新型非甾体化合物，其可用于治疗与糖皮质激素受体，AP-1和/或NF-κB活性的调节相关的疾病，包括肥胖症，糖尿病，炎症和免疫疾病，并且具有 式（I）其立体异构体，或其溶剂合物，或其前药，或其药学上可接受的盐，其中Z为CONR1R2或CH2NR1R2，并且其中X1-X4和/或X5-X8中的至少两个为N或NR18 ，R，R a，R b，R c，R d，R 1，R 2和R 18如本文所定义。 还提供了治疗肥胖症，糖尿病和包含所述化合物的炎性或免疫相关疾病的药物组合物和方法。

公开(公告)号：US20090075995A1

公开(公告)日：2009-03-19

申请号：US11835438

申请日：2007-08-08

Applicant: David S. Weinstein ,  Ping Chen ,  T.G. Murali Dhar ,  Jingwu Duan ,  Hua Gong ,  Bin Jiang ,  Bingwei Vera Yang ,  Arthur M. Doweyko

Inventor： David S. Weinstein ,  Ping Chen ,  T.G. Murali Dhar ,  Jingwu Duan ,  Hua Gong ,  Bin Jiang ,  Bingwei Vera Yang ,  Arthur M. Doweyko

IPC: A61K31/5377 ,  A61K31/436 ,  C07D491/052 ,  A61P31/12 ,  A61K31/427 ,  C07D417/12

CPC classification number: C07D417/12 ,  C07D277/46 ,  C07D405/12 ,  C07D417/14 ,  C07D491/04

Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity, including inflammatory and immune diseases, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which: Z is heterocyclo or heteroaryl; A is a 5- to 8-membered carbocyclic ring or a 5- to 8-membered heterocyclic ring; B is a cycloalkyl, cycloalkenyl, aryl, heterocyclo, or heteroaryl ring, wherein each ring is fused to the A ring on adjacent atoms and optionally substituted by one to four groups which are the same or different and are independently selected from R5, R6, R7, and R8; J1, J2, and J3 are at each occurrence the same or different and are independently -A1QA2-; Q is a bond, O, S, S(O), or S(O)2; A1 and A2 are the same or different and are at each occurrence independently selected from a bond, C1-3alkylene, substituted C1-3alkylene, C2-4alkenylene, and substituted C2-4alkenylene, provided that A1 and A2 are chosen so that ring A is a 5- to 8-membered carbocyclic or heterocyclic ring; R1 to R11 are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.

Abstract translation: 提供了新的非甾体化合物，其可用于治疗与式（I）结构的糖皮质激素受体，AP-1和/或NF-κB活性（包括炎症和免疫疾病）调节相关的疾病：对映异构体 ，非对映异构体或其互变异构体，或其前药酯或其药学上可接受的盐，其中：Z是杂环或杂芳基; A是5至8元碳环或5至8元杂环; B是环烷基，环烯基，芳基，杂环基或杂芳基环，其中每个环与相邻原子上的A环稠合并任选地被一至四个相同或不同的基团取代，并且独立地选自R5，R6， R7和R8; J1，J2和J3各自出现相同或不同，独立地为-A1QA2-; Q是键，O，S，S（O）或S（O）2; A1和A2相同或不同，并且在每次出现时独立地选自键，C1-3亚烷基，取代的C1-3亚烷基，C2-4亚烯基和取代的C2-4亚烯基，条件是选择A1和A2使得环A为 5-至8-元碳环或杂环; R1至R11如本文所定义。 还提供了使用所述化合物治疗炎性或免疫相关疾病和肥胖症和糖尿病的药物组合物和方法。

公开(公告)号：US20080310542A1

公开(公告)日：2008-12-18

申请号：US12095194

申请日：2006-11-24

Applicant: Xiqi Gao ,  Xiaohu You ,  Bin Jiang ,  Zhiwen Pan ,  Yuan Zhang

Inventor： Xiqi Gao ,  Xiaohu You ,  Bin Jiang ,  Zhiwen Pan ,  Yuan Zhang

IPC: H04L27/28

CPC classification number: H04L1/0028 ,  H04B7/0413 ,  H04B7/0456 ,  H04B7/0617 ,  H04B7/0621 ,  H04B7/0636 ,  H04L1/0003 ,  H04L1/0009 ,  H04L1/0625 ,  H04L1/0631 ,  H04L25/0204 ,  H04L25/0228 ,  H04L25/03955 ,  Y02D70/444

Abstract: An adaptive transmission scheme of the channel environment in the multi-antenna wireless transmission system can raise the spectrum use rate and power efficiency of the communication system in fast. Comparing with the traditional single antenna input and single antenna output, the channel environment in MIMO wireless communication system is more complex. When the terminal is moving, the different types of channels between terminal and base station can be gone through and then its capacity can be changed more largely. It is characterized in: at first, obtaining the statistical channel information at the receiving end using the result of channel estimation; then, quantizing and encoding the obtained statistical channel information to get feedback bit information and send the feedback bit information to the transmitting end through a feedback channel; thereby using statistical information, the sending end calculates link self-adapting control parameters, which are used for controlling coding modulation and sending the pre-code; the sending end obtains the digital base band transmission signal using a characteristic mode transmission method and a random virtual space selection transmission method, and the receiving end carries out self-adapting receiving by the same parameters.

Abstract translation: 多天线无线传输系统中的信道环境的自适应传输方案可以快速提高通信系统的频谱利用率和功率效率。 与传统的单天线输入和单天线输出相比，MIMO无线通信系统中的信道环境更加复杂。 当终端移动时，终端和基站之间的不同类型的信道可以通过，其容量可以更大地改变。 其特征在于：首先，使用信道估计结果在接收端获取统计信道信息; 然后对获得的统计信道信息进行量化和编码以获得反馈比特信息，并通过反馈信道将反馈比特信息发送到发送端; 从而使用统计信息，发送端计算用于控制编码调制和发送预编码的链路自适应控制参数; 发送端使用特征模式发送方法和随机虚拟空间选择发送方法获得数字基带发送信号，接收端通过相同的参数进行自适应接收。